Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Gains from Investment Securities: 2011-2025

Historic Gains from Investment Securities for Abeona Therapeutics (ABEO) over the last 7 years, with Sep 2025 value amounting to $394,921.

  • Abeona Therapeutics' Gains from Investment Securities fell 97.39% to $394,921 in Q3 2025 from the same period last year, while for Sep 2025 it was $394,921, marking a year-over-year decrease of 98.64%. This contributed to the annual value of $584,700 for FY2024, which is 226.65% up from last year.
  • Latest data reveals that Abeona Therapeutics reported Gains from Investment Securities of $394,921 as of Q3 2025, which was down 14.68% from $462,853 recorded in Q2 2025.
  • Abeona Therapeutics' Gains from Investment Securities' 5-year high stood at $15.2 million during Q3 2024, with a 5-year trough of -$6.8 million in Q4 2024.
  • Over the past 3 years, Abeona Therapeutics' median Gains from Investment Securities value was $462,853 (recorded in 2025), while the average stood at $2.0 million.
  • Examining YoY changes over the last 5 years, Abeona Therapeutics' Gains from Investment Securities showed a top increase of 6,165.00% in 2022 and a maximum decrease of 305,100.00% in 2022.
  • Abeona Therapeutics' Gains from Investment Securities (Quarterly) stood at -$16,000 in 2021, then crashed by 33,575.00% to -$5.4 million in 2022, then skyrocketed by 178.51% to $4.2 million in 2023, then tumbled by 260.17% to -$6.8 million in 2024, then crashed by 97.39% to $394,921 in 2025.
  • Its Gains from Investment Securities was $394,921 in Q3 2025, compared to $462,853 in Q2 2025 and $531,700 in Q1 2025.